Who We Are

Founded in 1981 in Boston, Massachusetts, Genzyme evolved from a tiny start-up to one of the world's leading biotech companies, with nearly 10,000 employees and operations in every region of the globe. Acquired by Sanofi in 2011, Genzyme now benefits from the reach and resources of one of the world’s largest pharmaceutical companies, with a shared commitment to improving the lives of patients.

Genzyme has long been known for our expertise in the class of rare genetic diseases known as lysosomal storage disorders (LSDs). LSDs remain the heart of our company today, but we have also expanded our focus to other rare diseases and multiple sclerosis.

Driven by our commitment to patients, we strive to develop strong relationships with patient communities and listen to their perspectives so that we can truly understand their needs. These collaborations guide us as we continue to push the boundaries of medicine and technology to develop new and better therapies where none existed before.

About Sanofi

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets, and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

	Investor Information For the complete story on Genzyme stock and other investor information, visit genzyme.com.

Privacy Policy - Canada USA | Terms and Conditions of Use | | © 2003-2013 Genzyme, a Sanofi company. All rights reserved.